Interaction of metabolic and haemodynamic factors in mediating experimental diabetic nephropathy

Diabetologia

Volumn 44, Issue 11, 2001, Pages 1957-1972

  Cooper, M E ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

CTGF; Endothelin; Glycation; Hypertension; Nephrin; Nephropathy angiotensin II; Protein kinase C; TGF ; VEGF

Indexed keywords

ALDOSE REDUCTASE INHIBITOR; ANTIHYPERTENSIVE AGENT; CONNECTIVE TISSUE GROWTH FACTOR; CYTOKINE; GROWTH FACTOR; MITOGEN ACTIVATED PROTEIN KINASE; NEPHRIN; POLYOL; PROTEIN KINASE C; PROTEIN KINASE C INHIBITOR; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN; VASOACTIVE AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; CONTROLLED STUDY; DIABETIC NEPHROPATHY; EXPERIMENTATION; GLOMERULOSCLEROSIS; GLYCATION; HEMODYNAMICS; INTERSTITIAL NEPHRITIS; KIDNEY TUBULE PRESSURE; METABOLISM; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PROTEINURIA; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SECOND MESSENGER;

ANIMALS; DIABETIC NEPHROPATHIES; DIABETIC RETINOPATHY; DISEASE MODELS, ANIMAL; HEMODYNAMIC PROCESSES;

EID: 0035204171     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001250100000     Document Type: Review

References (185)

1. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): Prospective observational study
2. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study
3. Pathophysiology of diabetic nephropathy
4. Putative pathophysiological role of growth factors and cytokines in experimental diabetic kidney disease
5. Experimental diabetic nephropathy: Is it relevant to the human disease
6. Treatment of hyperlipidemia reduces glomerular injury in obese Zucker rats (OZ)
7. Animal models of spontaneous diabetic kidney disease
8. A New Model of Diabetic Nephropathy with Progressive Renal Impairment in the Transgenic (mRen-2)27 Rat (Tgr)
9. Longterm prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice
10. Effects of genetic hypertension on diabetic nephropathy in the rat - Functional and structural characteristics
11. Nephropathy in model combining genetic hypertension with experimental diabetes. Enalapril versus hydralazine and metoprolol therapy
12. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension
13. The case for intrarenal hypertension in the initiation and progression of diabetic and other glomerulopathies
14. Predominance of hemodynamic rather than metabolic factors in the pathogenesis of diabetic glomerulopathy
15. Fulminant hypertension in transgenic rats harbouring the mouse Ren-2 gene
16. Effects of endothelin or angiotensin II receptor blockade on diabetes in the transgenic (mRen-2)27 rat
17. Role of angiotensin II in diabetic nephropathy
18. Renal reninangiotensin system in diabetes: Functional, immunohistochemical, and molecular biological correlations
19. The renin-angiotensin system in streptozotocin-induced diabetes mellitus in the rat
20. Increased bradykinin and 'normal' angiotensin peptide levels in streptozotocin-diabetic Sprague Dawley and TGR(mRen-2) rats
21. Molecular mechanisms of glucose action on angiotensinogen gene expression in rat proximal tubular cells
22. Role of angiotensin II in glucose-induced inhibition of mesangial matrix degradation
23. Pathological expression of renin and angiotensin II in the renal tubule after subtotal nephrectomy - Implications for the pathogenesis of tubulointerstitial fibrosis
24. Early diabetes mellitus stimulates proximal tubule renin mRNA expression in the rat
25. Angiotensin II and its receptors in the diabetic kidney
26. The role of angiotensin II in diabetic nephropathy: Emphasis on nonhemodynamic mechanisms
27. Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells
28. Transforming growth factor β1 and renal injury following subtotal nephrectomy in the rat: Role of the renin-angiotensin system
29. Expression of transforming growth factor-β1 and type IV collagen in the renal tubulointerstitium in experimental diabetes: Effects of angiotensin converting enzyme inhibition
30. Role of protein kinase C in angiotensin II-induced constriction of renal microvessels
31. Angiotensin II activates nuclear transcription factor kappa B through AT(1) and AT(2) in vascular smooth muscle cells - Molecular mechanisms
32. Cell cycle regulatory proteins in renal disease: Role in hypertrophy, proliferation, and apoptosis
33. Apoptosis and angiotensin I; yet another renal regulatory system
34. The role of angiotensin II and bradykinin in experimental diabetic nephropathy: Functional and structural studies
35. Cell cycle regulation in diabetic nephropathy
36. Pathogenesis, prevention and treatment of diabetic nephropathy
37. Angiotensin type 2 receptor is expressed in the adult rat kidney and promotes cellular proliferation and apoptosis
38. Short- and long-term effect of angiotensin II receptor blockade in rats with experimental diabetes
39. Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy
40. Longterm comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy
41. The effect of angiotensin converting enzyme inhibition on diabetic nephropathy
42. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: The candesartan and Lisinopril microalbuminuria (CALM) study
43. Additive hypotensive and antialbuminuric effects of angiotensin converting enzyme inhibition and angiotensin receptor antagonism in diabetic spontaneously hypertensive rat
44. Renoprotective and anti-hypertensive effects of combined valsartan and perindopril in progressive diabetic nephropathy in the transgenic (mRen-2)27 rat
45. Mechanism of progression of renal disease - Current hemodynamic concepts
46. Endothelin antagonists
47. Vasopressin receptor antagonism - A therapeutic option in heart failure and hypertension
48. New hormonal blockade strategies in cardiovascular disease
49. Antihypertensive and antihypertrophic effects of omapatrilat in SHR
50. Vasopeptidase inhibition attenuates the progression of renal injury in subtotal nephrectomised rats
51. Dual inhibition of neutral endopeptidase and angiotensin-converting enzyme in rats with hypertension and diabetes mellitus
52. Diabetes mellitus increases endothelin-1 gene transcription in rat kidney
53. Gene expression for endothelins and their receptors in glomeruli of diabetic rats
54. Blockade of the renin-angiotensin and endothelin systems on progressive renal injury
55. Unselective inhibition of endothelin receptors reduces renal Dysfunction in experimental diabetes
56. Is there a role for endothelin antagonists in diabetic renal disease?
57. Role of EDRF (nitric oxide) in diabetic renal hyperfiltration
58. Enhanced, unaltered and impaired nitric oxide-mediated endothelium-dependent relaxation in experimental diabetes mellitus: Importance of disease duration
59. Role of endothelium-derived nitric oxide in the pathogenesis of the renal hemodynamic changes of experimental diabetes
60. Abnormal renal hemodynamic response to reduced renal perfusion pressure in diabetic rats: Role of NO
61. Nitric oxide synthase isoforms and glomerular hyperfiltration in early diabetic nephropathy
62. Increased expression of endothelial cell nitric oxide synthase (ecNOS) in afferent and glomerular endothelial cells is involved in glomerular hyperfiltration of diabetic nephropathy
63. Relative contributions of advanced glycation and nitric oxide synthase inhibition to aminoguanidine-mediated renoprotection in diabetic rats
64. An analysis of renal nitric oxide contribution to hyperfiltration in diabetic rats
65. Expression of nitric oxide synthase in macula densa in streptozotocin diabetic rats
66. Renal nitric oxide production during the early phase of experimental diabetes mellitus
67. Increased nitrotyrosine staining in kidneys from patients with diabetic nephropathy
68. Lilly Lecture 1993. Glycation and diabetic complications
69. Role of oxidative stress in diabetic complications: A new perspective on an old paradigm
70. New biomarkers of Maillard reaction damage to proteins
71. Pentosidine: A molecular marker for the cumulative damage to proteins in diabetes, aging, and uremia
72. Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozocin-induced diabetic rat
73. Advanced glycosylation end products in experimental murine diabetic nephropathy: Effect of islet grafting and of aminoguanidine
74. The effects of aminoguanidine in preventing experimental diabetic nephropathy are related to duration of treatment
75. Aminoguanidine, a novel inhibitor of nitric oxide formation, prevents diabetic vascular dysfunction
76. Renoprotective effects of a novel inhibitor of advanced glycation
77. An agent cleaving glucose-derived protein crosslinks in vitro and in vivo
78. Breakers of advanced glycation end products restore large artery properties in experimental diabetes
79. Cloning and expression of a cell surface receptor for advanced glycation end products of proteins
80. Molecular identity and distribution of advanced glycation end-products receptors: Relationship of p60 to OST-48 and p90 to 80K-H membrane proteins
81. Antibacterial activity of lysozyme and lactoferrin is inhibited by binding of advanced glycation-modified proteins to a conserved motif
82. Macrophage scavenger receptor mediates the endocytic uptake and degradation of advanced glycation end products of the Maillard reaction
83. Enhanced cellular oxidantstress by the interaction of advanced glycation end products with their receptors binding proteins
84. N-epsilon-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression
85. Differential expression of renal AGE-receptor genes in NOD mice: Possible role in nonobese diabetic renal disease
86. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts
87. Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease
88. Advanced glycation end products and the receptor for advanced glycated end products co-localise in organs susceptible to diabetic microvascular injury: Immunohistochemical studies
89. Effect of diabetes and aminoguanidine therapy on renal advanced glycation end-product binding
90. Aminoguanidine ameliorates overexpression of prosclerotic growth factors and collagen deposition in experimental diabetic nephropathy
91. Suppression of transforming growth factor beta and vascular endothelial growth factor in diabetic nephropathy in rats by a novel advanced glycation end product inhibitor, OPB-9195
92. Aldose reductase inhibitors: Therapeutic implications for diabetic complications
93. Aldose reductase and the role of the polyol pathway in diabetic nephropathy
94. Sorbitol, phosphoinositides, and sodium-potassium-ATPase in the pathogenesis of diabetic complications
95. An aldose reductase inhibitor prevents glucose-induced increase in transforming growth factor-beta and protein kinase c activity in cultured human mesangial cells
96. The effect of aldose reductase inhibitors on glomerular prostaglandin production and urinary albumin excretion in experimental diabetes mellitus
97. Sorbinil prevents glomerular hyperperfusion in diabetic rats
98. Effects of sorbinil on glomerular structure and function in long-term- Diabetic rats
99. Administration of ascorbic acid and an aldose reductase inhibitor (Tolrestat) in diabetes - Effect on urinary albumin excretion
100. Reduction of glomerular hyperfiltration in normoalbuminuric IDDM patients by 6 mo of aldose reductase inhibition
101. Role of the hexosamine biosynthetic pathway in diabetic nephropathy
102. Overexprescion of GFAT activates PAI-1 promoter in mesangial cells
103. Overexpression of glutamine: Fructose-6-phosphate-amidotransferase induces transforming growth factor-beta 1 synthesis in NIH-3T3 fibroblasts
104. Overexpression of glucose transporters in rat mesangial cells cultured in a normal glucose milieu mimics the diabetic phenotype
105. D-glucose stimulates mesangial cell GLUT1 expression and basal and IGF- I-sensitive glucose uptake in rat mesangial cells: Implications for diabetic nephropathy
106. Glucose transporters control gene expression of aldose reductase, PKCalpha, and GLUT1 in mesangial cells in vitro
107. Antisense GLUT-1 protects mesangial cells from glucose induction of GLUT-1 and fibronectin expression
108. Changes in facilitative glucose transporter messenger ribonucleic acid levels in the diabetic rat kidney
109. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage
110. The relative roles of advanced glycation, oxidation and aidose reductase inhibition in the development of experimental diabetic nephropathy in the Sprague-Dawley rat
111. Reactive oxygen species as glucose signaling molecules in mesangial cells cultured under high glucose
112. AGEs induce oxidative stress and activate protein kinase C-beta(II) in neonatal mesangial cells
113. Lipid peroxidation in isolated rat nephron segments
114. High glucose inhibits glucose uptake in renal proximal tubule cells by oxidative stress and protein kinase C
115. Reactive oxygen species enhances endothelin-1 production of diabetic rat glomeruli in vitro and in vivo
116. Characterization of the mechanism for the chronic activation of diacylglycerol-protein kinase c pathway in diabetes and hypergalactosemia
117. Activation of protein kinase-c reduces thromboxane receptors in glomeruli and mesangial cells
118. Characterization of protein kinase c beta isoform activation on the gene expression of transforming growth factor-beta, extracellular matrix components, and prostanoids in the glomeruli of diabetic rats
119. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor
120. Amelioration of accelerated diabetic mesangial expansion by treatment with a PKC beta inhibitor in diabetic db/db mice, a rodent model for type 2 diabetes
121. Prevention of albuminuria by aminoguanidine or ramipril in streptozotocin-induced diabetic rats is associated with the normalization of glomerular protein kinase C
122. Aminoguanidine and ramipril prevent diabetes-induced increases in protein kinase C activity in glomeruli, retina and mesenteric artery
123. Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase c in vivo and suppressed by an orally effective beta-isoform-selective inhibitor
124. Role of vascular endothelial growth factor in diabetic nephropathy
125. Antioxidant inhibition of protein kinase c signaled increases in transforming growth factor-beta in mesangial cells
126. Mechanisms of disease - Nuclear factor-kappa-b- A pivotal transcription factor in chronic inflammatory diseases
127. Activation of nuclear factor-kappa-b in cultured endothelial cells by increased glucose concentration - Prevention by Calphostin C
128. Characterization and functional analysis of the promoter of rage, the receptor for advanced glycation end products
129. Inhibition of nuclear factor-kappa B activation reduces cortical tubulointerstitial injury in proteinuric rats
130. Mitogen-activated protein kinases as glucose transducers for diabetic complications
131. Mechanism of transforming growth factor-beta 1 signaling: Role of the mitogen-activated protein kinase
132. Glucose or diabetes activates p38 mitogen-activated protein kinase via different pathways
133. Small heat shock protein alteration provides a mechanism to reduce mesangial cell contractility in diabetes and oxidative stress
134. Mitogen-activated protein kinase cascade is activated in glomeruli of diabetic rats and glomerular mesangial cells cultured under high glucose conditions
135. Activation of the receptor for advanced glycation end products triggers a p21(ras)-dependent mitogen-activated protein kinase pathway regulated by oxidant stress
136. Effect of glucose on stress-activated protein kinase activity in mesangial cells and diabetic glomeruli
137. High levels of glucose stimulate angiotensinogen gene expression via the p38 mitogen-activated protein kinase pathway in rat kidney proximal tubular cells
138. Role of mitogen-activated protein kinases as downstream effectors of transforming growth factor-beta in mesangial cells
139. TGF-beta signal transduction
140. Smad proteins and transforming growth factor-beta signaling
141. Transforming growth factor beta in tissue fibrosis
142. Elevated glucose stimulates TGF-beta gene expression and bioactivity in proximal tubule
143. Vascular hypertrophy in experimental diabetes: Role of advanced glycation end products
144. Interaction of angiotensin II and mechanical stretch on vascular endothelial growth factor production by human mesangial cells
145. Angiotensin II-stimulated expression of transforming growth factor beta in renal proximal tubular cells - Attenuation after stable transfection with the C-mas oncogene
146. Vascular and glomerular expression of endothelin-1 in normal human kidney
147. Role of hyperlipidemia in progressive renal disease: Focus on diabetic nephropathy
148. F-2-isoprostanes mediate high glucose-induced TGF-beta synthesis and glomerular proteinuria in experimental type I diabetes
149. Glycated albumin stimulates TGF-beta 1 production and protein kinase C activity in glomerular endothelial cells
150. Glucose stimulation of transforming growth factor-beta bioactivity in mesangial cells is mediated by thrombospondin-1
151. IHG-2, a mesangial cell gene induced by high glucose, is human gremlin - Regulation by extracellular glucose concentration, cyclic mechanical strain, and transforming growth factor-beta 1
152. Deranged transcriptional regulation of cell-volume-sensitive kinase hSGK in diabetic nephropathy
153. Diabetic kidney disease is linked to elevated expression of transforming growth factor-ß
154. Renal expression of transforming growth factor-beta inducible gene-h3 (beta-Ig-H3) in normal and diabetic rats
155. Glycosaminoglycan therapy prevents TGF-beta 1 overexpression and pathologic changes in renal tissue of long-term diabetic rats
156. The renal expression of transforming growth factor-beta isoforms and their receptors in acute and chronic experimental diabetes in rats
157. Stimulation of TGF-beta type II receptor by high glucose in mouse mesangial cells and in diabetic kidney
158. Angiotensin converting enzyme inhibitor suppresses glomerular transforming growth factor beta receptor expression in experimental diabetes in rats
159. Glomerulosclerosis induced by in vivo transfection of transforming growth factor-beta or platelet-derived growth factor gene into the rat kidney
160. Effect of a specific endothelin receptor a antagonist on mrna levels for extracellular matrix components and growth factors in diabetic glomeruli
161. Selective Inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase in of the 2-phenylaminopyrimidine class
162. PDGF signal transduction inhibition ameliorates experimental mesangial proliferative glomerulonephritis
163. Regulation of connective tissue growth factor activity in cultured rat mesangial cells and its expression in experimental diabetic glomerulosclerosis
164. Connective tissue growth factor/IGFBP-rP2 is up-regulated by advanced glycosylatiuon end-products in human fibroblasts: A potential mechanism for expansion of extracellular matrix in diabetes mellitus
165. Vascular endothelial growth factor inocular fLuid of patients with diabetic retinopathy and other retinal disorders
166. Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes
167. Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes
168. Expression of vascular endothelial growth factor in response to high glucose in rat mesangial cells
169. Advanced glycation end products increase retinal vascular endothelial growth factor expression
170. Angiotensin II increases vascular permeability factorgene expression by human vascular smooth muscle cells
171. Mechanical stretch induces vascular permeability factor in human mesangial cells - Mechanisms of signal transduction
172. Angiotensin converting enzyme inhibition reduces retinal overexpression of vascular endothelial growth factor and hyperpermeability in experimental diabetes
173. Retinal neovascularization is prevented by blockade of the reninangiotensin system
174. Increased epidermal growth factor in experimental diabetes related kidney growth in rats
175. The role of growth hormone, insulin-like growth factors (Igfs), and Igf-binding proteins in experimental diabetic kidney disease
176. Octreotide prevents the early increase in renal insulin-like growth factor binding protein 1 in streptozotocin diabetic rats
177. Focal induction of IGF binding proteins in proximal tubules of diabetic rat kidney
178. Nephrin is specifically located at the slit diaphragm of glomerular podocytes
179. Cloning of rat nephrin: Expression in developing glomeruli and in proteinuric states
180. Irbesartan normalises the deficiency in glomerular nephrin expression in a model of diabetes and hypertension
181. Blocking angiotensin II synthesis/activity preserves glomerular nephrin in rats with severe nephrosis
182. Glomerular expression of nephrin is decreased in acquired human nephrotic syndrome
183. New insights into the pathogenesis of proteinuria
184. Preserving renal function in adults with hypertension and diabetes: A consensus approach
185. Gene expression profile in streptozotocin-induced diabetic mice kidneys undergoing glomerulosclerosis